Tesaro, AnaptysBio collaborate on immune checkpoint inhibitors

Cancer drug developer Tesaro entered the hot immuno-oncology space with an exclusive, worldwide license and collaboration agreement for antibodies from AnaptysBio that target three different immune checkpoint receptors.

Cancer drug developer Tesaro entered the hot immuno-oncology space with an exclusive, worldwide license and collaboration agreement for antibodies from AnaptysBio that target three different immune checkpoint receptors.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By 

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By 

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By 

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

More from Therapy Areas

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By 

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By 

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.